Gene engineering recombined vaccine of carcinoma of cervix uterus

A cervical cancer and genetic engineering technology, which is applied in the field of recombinant vaccines for the treatment and prevention of cervical cancer, can solve the problems such as the need for further confirmation of the immune effect of the vaccine and the problem of carcinogenesis.

Inactive Publication Date: 2005-05-18
肖啸 +1
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, according to literature reports, most cervical cancer vaccines are produced with whole viruses, and the oncogenes carried by the viruses themselves are present in the products, which have potential carcinogenic effects; at the same time, the immune effects of some vaccines need to be further confirmed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gene engineering recombined vaccine of carcinoma of cervix uterus
  • Gene engineering recombined vaccine of carcinoma of cervix uterus
  • Gene engineering recombined vaccine of carcinoma of cervix uterus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0017] The following describes in detail with reference to the accompanying drawings and the related concepts and methods of the present invention.

[0018] 1. Relevant characteristics of recombinant adeno-associated virus:

[0019] Adeno-associated virus (AAV) is a single-stranded virus that has been extensively studied as a vector for gene therapy. As a defective human parvovirus, AAV possesses many natural attributes that make it a vector for human gene therapy, such as non-pathogenicity, site-directed integration capability, and a broad host range (human, simian, murine, canine, and avian). )Wait. Unlike other viral vectors (such as vaccinia virus or adenovirus, etc.) that have been used in vaccines, AAV vectors do not express any viral genes. The only viral DNA that must be included in an AAV vector is its 145 bp inverted terminal repeat. The expressed gene carried by the AAV vector expresses only the cloned gene itself.

[0020] Previous reports have demonstrated tha...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to bioengineering technology, and is a kind of recombinant gene engineering vaccine for carcinoma of uterine cervix. The recombinant gene engineering vaccine is established on the basis of gene engineering, and has AAV vector to express HPV16 and HPV18 serum type E7 protein to induce the body's HPV specific immunological reaction and to produce uterine cervix carcinoma preventing and treating effect. Owing to the spot mutation of the destination gene E7, the heat-sensitive fusion of tubercule bacillus and the destination gene and the vector AAV, excellent immunogen capable of expressing in body for long time without side effect is constituted.

Description

technical field [0001] The present invention belongs to a biological preparation. Specifically, it is a recombinant vaccine for the treatment and prevention of cervical cancer obtained by genetic method. technical background [0002] Cervical cancer is one of the most widespread malignancies, with approximately 500,000 new cases worldwide and approximately 200,000 deaths annually from cervical cancer. At present, the methods and technical means used for the treatment of cervical cancer mainly include: surgical treatment; radiotherapy; chemotherapy. Compared with these methods, which bring more or less suffering or poor prognosis to patients, specific preventive or therapeutic vaccines can overcome the above disadvantages. At present, vaccine research for cervical cancer has been carried out worldwide, and some countries have entered the clinical trial stage, such as the United States, the United Kingdom, Japan, Australia, France and my country; in cli...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61P35/00C12N7/01
Inventor 肖啸周立桥
Owner 肖啸
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap